These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30184174)

  • 1. Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy.
    Malek V; Gaikwad AB
    Cardiovasc Res; 2019 Feb; 115(2):373-384. PubMed ID: 30184174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
    Malek V; Sharma N; Sankrityayan H; Gaikwad AB
    Life Sci; 2019 Mar; 221():159-167. PubMed ID: 30769114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone Acetylation Regulates Natriuretic Peptides and Neprilysin Gene Expressions in Diabetic Cardiomyopathy and Nephropathy.
    Malek V; Sharma N; Gaikwad AB
    Curr Mol Pharmacol; 2019; 12(1):61-71. PubMed ID: 30465518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
    Malek V; Sharma N; Gaikwad AB
    Pharmacol Rep; 2019 Oct; 71(5):958-967. PubMed ID: 31470292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan improves cardiac fibrosis in diabetes through peroxisome proliferator activated receptor δ (PPARδ): from bedside to bench.
    Chang WT; Cheng JT; Chen ZC
    Cardiovasc Diabetol; 2016 Aug; 15(1):113. PubMed ID: 27519769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice.
    Chen Y; Du J; Zhao YT; Zhang L; Lv G; Zhuang S; Qin G; Zhao TC
    Cardiovasc Diabetol; 2015 Aug; 14():99. PubMed ID: 26245924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telmisartan and esculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, and H2B histone modifications.
    Kadakol A; Malek V; Goru SK; Pandey A; Gaikwad AB
    Indian J Pharmacol; 2017; 49(5):348-356. PubMed ID: 29515275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with crocin improves cardiac dysfunction by normalizing autophagy and inhibiting apoptosis in STZ-induced diabetic cardiomyopathy.
    Feidantsis K; Mellidis K; Galatou E; Sinakos Z; Lazou A
    Nutr Metab Cardiovasc Dis; 2018 Sep; 28(9):952-961. PubMed ID: 30017436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid.
    Li CJ; Lv L; Li H; Yu DM
    Cardiovasc Diabetol; 2012 Jun; 11():73. PubMed ID: 22713251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial Effects of Combined AT1 Receptor/Neprilysin Inhibition (ARNI) Versus AT1 Receptor Blockade Alone in the Diabetic Eye.
    Prasad T; Roksnoer LC; Zhu P; Verma A; Li Y; Batenburg WW; de Vries R; Danser AH; Li Q
    Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6722-6730. PubMed ID: 27951594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic administration of the nitroxyl donor 1-nitrosocyclo hexyl acetate limits left ventricular diastolic dysfunction in a mouse model of diabetes mellitus in vivo.
    Cao N; Wong YG; Rosli S; Kiriazis H; Huynh K; Qin C; Du XJ; Kemp-Harper BK; Ritchie RH
    Circ Heart Fail; 2015 May; 8(3):572-81. PubMed ID: 25737497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
    Ge Q; Zhao L; Ren XM; Ye P; Hu ZY
    Exp Biol Med (Maywood); 2019 Sep; 244(12):1028-1039. PubMed ID: 31262190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet as a surrogate therapy for diabetic cardiomyopathy in rats through AMPK-mediated promotion of mitochondrial and autophagic function.
    Elrashidy RA; Ibrahim SE
    Toxicol Appl Pharmacol; 2021 Jun; 421():115533. PubMed ID: 33848515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat.
    Tate M; Deo M; Cao AH; Hood SG; Huynh K; Kiriazis H; Du XJ; Julius TL; Figtree GA; Dusting GJ; Kaye DM; Ritchie RH
    Diab Vasc Dis Res; 2017 Sep; 14(5):423-433. PubMed ID: 28565941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight fucoidan alleviates cardiac dysfunction in diabetic Goto-Kakizaki rats by reducing oxidative stress and cardiomyocyte apoptosis.
    Yu X; Zhang Q; Cui W; Zeng Z; Yang W; Zhang C; Zhao H; Gao W; Wang X; Luo D
    J Diabetes Res; 2014; 2014():420929. PubMed ID: 25525607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
    Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T
    Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS/TLR-4 signaling pathway.
    Liu ZW; Wang JK; Qiu C; Guan GC; Liu XH; Li SJ; Deng ZR
    Acta Pharmacol Sin; 2015 Mar; 36(3):323-33. PubMed ID: 25619390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of diabetic cardiomyopathy by relying on kirenol to suppress inflammation in a diabetic rat model.
    Wu B; Huang XY; Li L; Fan XH; Li PC; Huang CQ; Xiao J; Gui R; Wang S
    J Cell Mol Med; 2019 Nov; 23(11):7651-7663. PubMed ID: 31565849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor blockade alone in hypertensive rats.
    Roksnoer LC; van Veghel R; de Vries R; Garrelds IM; Bhaggoe UM; Friesema EC; Leijten FP; Poglitsch M; Domenig O; Clahsen-van Groningen MC; Hoorn EJ; Jan Danser AH; Batenburg WW
    Kidney Int; 2015 Jul; 88(1):109-20. PubMed ID: 25830765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis.
    Pandey A; Gaikwad AB
    Biochem Biophys Res Commun; 2017 Jun; 487(4):827-833. PubMed ID: 28456626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.